Invitrogen Corporation Introduces Innovation that Speeds Regulatory Filings and Time to Market for Biotherapeutics Manufacturers

CARLSBAD, Calif.--(BUSINESS WIRE)--Invitrogen, a division of Life Technologies (NASDAQ:LIFE), today announced the launch of the GIBCO® OptiCHO™ Protein Express Kit, a new integrated solution for simple and efficient development of serum-free, stable cell lines for biotherapeutic development. This is the first kit of its kind to provide cells banked under cGMP conditions, enabling biotherapeutics manufacturers to speed regulatory submissions and time to market.